A recent study published in Alzheimer’s & Dementia outlines a promising approach to the early diagnosis of Dementia with Lewy Bodies (DLB), a neurodegenerative disease that is often misdiagnosed, delaying access to appropriate care. DLB, which ranks as the second most common form of dementia after Alzheimer’s Disease, can be difficult to distinguish from other types of dementia, making early diagnosis critical for effective treatment.
The research team, led by Dr. Ece Bayram, assistant professor of neurology at the University of Colorado Anschutz Medical Campus, aimed to create a cognitive profile for DLB that could be applied in clinical settings. While research criteria for identifying DLB exist, they are typically limited to academic environments. By pooling data from existing studies, the researchers developed a cognitive profile that could help differentiate DLB from Alzheimer’s Disease at the pre-dementia stage, before symptoms of full-blown dementia appear.
“By synthesizing information from a range of research studies, we have developed a cognitive profile that can distinguish DLB from Alzheimer’s before dementia fully manifests,” said Dr. Bayram. “This will better inform the direction of care for individuals with these conditions.”
Findings from the Study
The study involved a meta-analysis of pre-dementia diagnoses, comparing cognitive symptoms in individuals with DLB and Alzheimer’s. Researchers found that at the pre-dementia stage, individuals with DLB exhibited more pronounced difficulties with attention, processing speed, and executive function. Conversely, they showed superior immediate recall and memory abilities compared to those with Alzheimer’s.
Dr. Bayram emphasized the importance of these findings in practical terms. “Identifying these cognitive profiles has allowed us to propose guidelines that clinicians can easily adopt, helping to tailor care plans more effectively,” she said. “Furthermore, this approach focuses on cognitive assessments, which are more accessible and cost-effective compared to imaging or invasive biomarker tests.”
Implications for Care
Early identification of DLB could have a profound impact on patient care. By diagnosing the condition before the onset of dementia, healthcare providers can implement treatment plans that are better suited to the individual’s specific needs. For example, people with DLB may have adverse reactions to commonly prescribed antipsychotic medications, such as haloperidol, which can worsen their condition. Identifying the disease early enables clinicians to avoid such harmful treatments and instead provide more effective symptomatic care.
Dr. Bayram stressed that this research is a step forward in dementia prevention and care. “We are witnessing an increasing number of treatment trials focused on modifying diseases like Alzheimer’s and Lewy body dementia. Validating clinical criteria to diagnose DLB before it progresses to dementia opens up the possibility of preventing it, rather than responding after significant brain damage has occurred,” she explained.
Advancing Dementia Diagnosis and Treatment
The study’s findings also underline the importance of clinical assessments in diagnosing DLB, offering a path for more widespread and accessible care. “These types of clinical assessments provide opportunities for everyone to receive proper care, even without access to a specialized center,” Dr. Bayram noted.
With the development of more precise and accessible diagnostic tools, there is hope that earlier intervention can significantly improve the quality of life for people living with DLB and other forms of dementia. The study represents a crucial advancement in the ongoing effort to improve dementia care and to prevent or delay the onset of debilitating symptoms.
You Might Be Interested In:
-
Cesarean Deliveries During Labor Linked to Risks in Future Pregnancies
-
AI-Driven Tool Revolutionizes Placenta Examination at Bedside
